Biotech wins $16.5 million in drug royalties dispute

Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the drug elsewhere.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Israel targets Teva over MS drug royalties

12 May 2022 The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

Americas

Novartis upholds MS drug patent at Fed Circ

4 January 2022 Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.

More on this story

Big Pharma

Israel targets Teva over MS drug royalties

12 May 2022 The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

Americas

Novartis upholds MS drug patent at Fed Circ

More on this story

Big Pharma

Israel targets Teva over MS drug royalties

12 May 2022 The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

Americas

Novartis upholds MS drug patent at Fed Circ